Format

Send to

Choose Destination
See comment in PubMed Commons below
Toxins (Basel). 2010 Oct;2(10):2340-58. doi: 10.3390/toxins2102340. Epub 2010 Oct 11.

Genomic damage in endstage renal disease-contribution of uremic toxins.

Author information

1
Institute of Pharmacology and Toxicology, University of Würzburg, Versbacher Straße 9, 97078 Würzburg, Germany. nicole.schupp@toxi.uni-wuerzburg.de

Abstract

Patients with end-stage renal disease (ESRD), whether on conservative, peritoneal or hemodialysis therapy, have elevated genomic damage in peripheral blood lymphocytes and an increased cancer incidence, especially of the kidney. The damage is possibly due to accumulation of uremic toxins like advanced glycation endproducts or homocysteine. However, other endogenous substances with genotoxic properties, which are increased in ESRD, could be involved, such as the blood pressure regulating hormones angiotensin II and aldosterone or the inflammatory cytokine TNF-α. This review provides an overview of genomic damage observed in ESRD patients, focuses on possible underlying causes and shows modulations of the damage by modern dialysis strategies and vitamin supplementation.

KEYWORDS:

dialysis; genotoxicity; uremic toxins

PMID:
22069557
PMCID:
PMC3153169
DOI:
10.3390/toxins2102340
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Multidisciplinary Digital Publishing Institute (MDPI) Icon for PubMed Central
    Loading ...
    Support Center